Plant Virus-Like Particle In Situ Vaccine for Intracranial Glioma Immunotherapy. by Kerstetter-Fogle, Amber et al.
UC San Diego
UC San Diego Previously Published Works
Title
Plant Virus-Like Particle In Situ Vaccine for Intracranial Glioma Immunotherapy.
Permalink
https://escholarship.org/uc/item/0172m488
Journal
Cancers, 11(4)
ISSN
2072-6694
Authors
Kerstetter-Fogle, Amber
Shukla, Sourabh
Wang, Chao
et al.
Publication Date
2019-04-10
DOI
10.3390/cancers11040515
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
cancers
Article
Plant Virus-Like Particle In Situ Vaccine for
Intracranial Glioma Immunotherapy
Amber Kerstetter-Fogle 1,†, Sourabh Shukla 2,† , Chao Wang 2, Veronique Beiss 2,
Peggy L. R. Harris 1, Andrew E. Sloan 1,3,4,* and Nicole F. Steinmetz 2,5,6,7,*
1 Department of Neurological Surgery, Case Western Reserve University, 10900 Euclid Avenue, Cleveland,
OH 44106, USA; aek20@case.edu (A.K.-F.); plr2@case.edu (P.L.R.H.)
2 Department of NanoEngineering, University of California San Diego, La Jolla, CA 92093, USA;
sshukla@ucsd.edu (S.S.); chw022@eng.ucsd.edu (C.W.); vbeiss@eng.ucsd.edu (V.B.)
3 University Hospitals-Cleveland Medical Center & the Seidman Cancer Center, Case Western Reserve
University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
4 Case Comprehensive Cancer Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland,
OH 44106, USA
5 Department of Radiology, University of California San Diego, La Jolla, CA 92093, USA
6 Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA
7 Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA
* Correspondence: Andrew.Sloan@uhhospitals.org (A.E.S.); nsteinmetz@ucsd.edu (N.F.S.)
† These authors contributed equally to this work.
Received: 12 March 2019; Accepted: 8 April 2019; Published: 10 April 2019


Abstract: Despite aggressive multi-modality treatment with surgery, radiation and chemotherapies,
malignant glioma inevitably recurs and has dismal survival rates. Recent progress in immunotherapy
has led to a resurgence of interest, and immunotherapies are being investigated for treatment of glioma.
However, the unique brain anatomy and a highly immunosuppressive glioma microenvironment
pose significant challenges to achieving efficacy. Thus, there is a critical need for assessment of
next-generation immunotherapies for glioma. In this study, we have investigated the efficacy of
the nanoparticle platform technology based on plant-derived Cowpea mosaic virus like particles
(empty CPMV or eCPMV) to instigate a potent immune response against intracranial glioma.
CPMV immunotherapy has been shown to efficiently reverse the immunosuppressive tumor
microenvironments in pre-clinical murine models of dermal melanoma and metastatic melanoma,
metastatic breast cancer, intraperitoneal ovarian cancer and in canine patients with oral melanoma.
In the present study, we demonstrate that in situ administration of CPMV immunotherapy in the
setting of glioma can effectively recruit unique subset of effector innate and adaptive immune cells to
the brain parenchyma while reducing immune suppressive cellular population, leading to regression
of intracranial glioma. The in situ CPMV nanoparticle vaccine offers a potent yet safe and localized
immunotherapy for intracranial glioma.
Keywords: intracranial glioma; immunotherapy; CPMV; viral nanoparticles; in situ vaccine
1. Introduction
Malignant glioma represents one of the most aggressive forms of cancer, with poor survival rates
that have not changed in the past three decades despite advancements in detection and treatment
modalities. Even with aggressive treatments including debulking, chemotherapy and radiation the
median survival rates for malignant glioma is 12 months, with a five-year relative survival of about
5% [1,2]. Glioma is also associated with high rates of morbidity due to damage to functional regions of
the brain. Surgery, radiation and chemotherapy are the mainstay of treatment regimens [3]. Malignant
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glioma is incurable surgically due to the infiltrative nature of these tumors and the surgeon’s inability
to safely resect a “margin” as is typical in most other solid cancers. The blood brain barrier (BBB) also
limits the penetration and clinical efficacy of most systemic chemotherapies [4]. Moreover, residual
tumor subpopulations resistant to radio- and chemotherapy eventually lead to recurrence and treatment
failure [5,6].
Success of immunotherapies for other solid tumors has led to renewed interest in immunotherapy for
gliomas [7,8]. However, the unique anatomical and physiological features of the brain are critical barriers
for such interventions [9]. The BBB, blood-cerebrospinal fluid (CSF) and blood-meningeal barriers
limit the entry of most small molecules as well as immune cells into the brain [10]. Recent advances
in the understanding of the central nervous system (CNS) have however, reversed the longstanding
theory that the brain is “immunologically privileged” and demonstrated that the BBB in patients with
malignant glioma is typically disrupted [11]. It has recently been noted that activated T cells can cross the
blood-brain-barrier, however, many of the inflammatory cells recruited to malignant gliomas contribute
to the highly immunosuppressive tumor microenvironment (TME). The glioma TME is characterized by
the prevalence of M2 polarized resident macrophages and microglial cells, myeloid-derived suppressor
cells (MDSCs), and a significantly smaller population of antigen presenting cells (APCs) including
exhausted dendritic cells (DCs) and T cells. The expression of vascular endothelial growth factor
(VEGF), tumor growth factor-β (TGF-β), prostaglandin E2 (PGE2) and interleukin-10 (IL-10) further
impair T cell proliferation and activation in response to pro-inflammatory signals, and downregulate
expression of major histocompatibility complexes (MHCs) and DC maturation [12]. Malignant
glioma also has a considerable infiltration of regulatory T cells (Tregs), which can further suppress
proliferation and activation of tumor infiltrating T lymphocytes [13]. Additionally, glioma stem cells
(GSCs) and glioma initiating cells (GIC), which drive glioma growth and invasion, contribute to
the immunosuppressive tumor microenvironment by recruiting tumor-supportive macrophages and
microglia, expressing immunosuppressive cytokines, and down regulating Toll-like receptors (TLRs)
thereby avoiding immune-mediated rejection [14].
Several immunotherapeutic approaches targeting gliomas are currently under pre-clinical
development and clinical evaluation. These include vaccines, adoptive T cell therapies, monoclonal
antibodies, checkpoint inhibitors and oncolytic virotherapies [8]. Immune escape with loss of targeted
antigens and glioma heterogeneity pose significant challenges for vaccines based on single or multiple
antigens, respectively [15]. Additionally, lack of a robust population of resident APCs in the brain
contributes to the reduced efficacy of glioma vaccines [12]. DC vaccines can overcome this hurdle by
reintroducing the patient’s own antigen pulsed DCs, however besides the technological challenges, this
approach suffers from low efficacy attributed to poor migration of DCs to secondary lymphoid tissues
for T cell activation [16]. Adoptive cell therapies (ACT) [17] that can circumvent DC dependence
have proven to be challenging in malignant gliomas due to their low densities within tumors, tumor
mediated exhaustion, and inefficient delivery through intravenous administrations [8,9]. Similarly,
restrictive delivery through the BBB and lack of effector cells or cytotoxic T cells (CTLs) renders
antibody drug conjugates and checkpoint inhibitors less effective as brain tumor treatments [18,19].
Oncolytic virotherapy utilizing genetically engineered mammalian viruses to selectively invade
glioma cells and express cytotoxic proteins has emerged as a potent therapeutic strategy for glioma.
Several oncolytic viruses have been studied including adenoviral vector Ad-RTS-hIL-12 that expresses
IL12 in the presence of an orally administered ligand, which can efficiently cross the BBB to reach the
tumor bed [20]. Similarly, engineered poliovirus PVSRIPO [21], oncolytic herpes simplex virus type-1
(oHSV-1) [22], measles virus [23] and Zika virus [24] have been shown to selectively replicate in and
lyse CNS tumor cells or tumor stem cells. While highly effective, applicability of virotherapy to the
brain remains under investigation, as uncontrolled inflammatory responses posing a threat to healthy
brain cells and delivery to the brain remain major hurdles [9].
Here, we present data from an in situ vaccine immunotherapy against malignant glioma utilizing
the plant virus like particles (VLPs) derived from Cowpea mosaic virus (CPMV). The CPMV VLPs
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lacks their nucleic acids and are referred to as empty CPMV (eCPMV). Recently, we have shown that
eCPMV (as well as CPMV) can induce anti-tumor responses in several murine models of cancers when
introduced into the tumor microenvironment (TME) as an in situ vaccine [25]. Results from canine
trials have also demonstrated efficacy in large animals with spontaneous melanoma [26]. Mechanistic
insights have indicated that CPMV stimulates an anti-tumor response through recruitment of innate
cells including monocytes, tumor infiltrating neutrophils (TINs) and natural killer (NK) cells, which
exert cancer cell toxicity resulting in the release of tumor antigens. Furthermore, through elevated
influx of APCs into the treated tumors, the CPMV in situ vaccine also facilitates priming of an adaptive
anti-tumor response with CD4+/CD8+ cells, therefore leading to systemic efficacy and immunological
memory [25]. Thus, CPMV activates the innate immune response, recalibrating the cancer–immunity
cycle to eliminate cancer cells via the adaptive immune system. Unlike the oncolytic viruses, plant
viruses are non-infectious and non-replicative in mammalian cells and the immune modulation is
driven by the unique proteinaceous architecture of the viral capsid. While previously validated in
various mouse model of dermal and metastatic melanoma, lung metastasis from breast cancer, and
intraperitoneal ovarian cancer, in the present study we set out to assess the efficacy of eCPMV in situ
vaccine against intracranial glioma using the syngeneic GL261 glioma mouse model.
2. Results
CPMV VLPs were produced by co-expression of the precursor to the L and S coat proteins
(VP60) and the viral proteinase (24K) using N. benthamiana plants and agroinfiltration as previously
described (Figure 1A) [27]. Typical purification yields are around 0.5 mg of VLP from each gram of
leaf tissue. The eCPMV VLP is a 30 nm-sized icosahedral particle devoid of nucleic acid and consists
of 60 copies each of a small (S) and large (L) coat protein subunits (Figure 1B) [28]. Post-purification
quality assurance of the self-assembled VLP was performed using TEM imaging and size exclusion
chromatography (SEC) confirming the presence of intact 30 nm particles with the typical elution
profiles from the Superose column; the absorbance ratio of A260:280 of 0.67 indicates that particles
devoid of RNA were produced (in contrast RNA-containing wild-type CPMV has a A260:280 of
1.8 [29] (Figure 1C,D). For imaging and tracking studies, N-hydroxysuccinimide chemistry was used
to conjugate the NHS esters of sulfo-Cy5 fluorophores to eCPMV capsid via the exposed lysine
residues [30] (Figure 1E). SDS-gel electrophoresis was used to confirm fluorescent tagging of the viral
coat proteins (Figure 1F). Unmodified eCPMV is represented by two distinct bands corresponding
to the ~24 kDa small coat protein (S-CP) subunit and the ~42 kDa large coat protein subunit (L-CP).
In eCPMV-Cy5 particles both these protein bands appear fluorescent when excited at 632 nm, indicating
successful dye conjugation. The ratio of Cy5 dyes per eCPMV particle were quantified by UV/Vis
spectroscopy and using the particles’ specific extinction coefficient εeCPMV of 1.28 mL mg−1 cm−1 at
280 nm and the molar extinction coefficient εCy5 of 271,000 at 660 nm. The reaction yielded ~50 dyes
per eCPMV.
To assess the potential for development of CPMV immunotherapy for treatment of glioma, we first
determined the feasibility of delivering VLP immunotherapy through intracranial injections into the
brain using fluorescently labeled eCPMV-Cy5 VLPs. All mouse studies were performed in compliance
with the Institutional Animal Care and Use Committee of Case Western Reserve University.
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Figure 1. eCPMV propagation, purification and characterization. (A) eCPMV VLPs were propagated 
using N. benthamiana plants; leaves were infiltrated when plants were 45 days old. (B) Structure of 
eCPMV, chimera image created using PDB file 1NY7 (CPMV) (C,D) Purified eCPMV particles were 
characterized for structural integrity using TEM and size exclusion chromatography (FPLC). (E) 
One-step-NHS chemistry was used to bioconjugate Cy5 dyes to the lysine residues on eCPMV CPs. 
(F) SDS-gel electrophoresis was used to confirm conjugation of Cy5 dyes to eCPMV coat proteins: 
the fluorescence derived from conjugated Cy5 is detected by exposing the gel to 632 nm excitation; 
the small (S) and large (L) protein are detected after protein staining (GelCodeTM Blue Safe protein 
stain) and visualization under white light. 
Following the intracranial injection, presence and retention of VLPs in brain was detected 
using ex vivo Maestro fluorescence imaging (Figure 2A). At 24 h post injection eCPMV can be 
readily detected at and around the injection site as evident by a strong fluorescent signal, whereas 
at day 7 the weak signal intensity suggested degradation and loss of proteinaceous VLPs from the 
brain microenvironment (Figure 2A). This observation is consistent with clearance of viral 
nanoparticles from other tissues [31]. During this period, mice were monitored for any signs of 
stress and discomfort resulting from particle administration and no apparent adverse effects were 
observed. We also evaluated intravenous route for eCPMV VLP administration as a mean of 
delivery immunotherapy to the brain. However, the VLPs were sequestered in the liver and spleen 
by the mononuclear phagocyte system (MPS) system with minimal doses reaching other tissues, 
including the brain. Therefore, we selected the intracranial injection as the mode of delivery for our 
studies. Based on the weeklong retention of eCPMV in brain, we set weekly intratumoral 
administration schedules for glioma immunotherapy. 
Figure 1. eCP V propagation, purification and characterization. (A) eCP V VLPs were propagated
using N. benthamiana plants; leaves were infiltrated when plants were 45 days old. (B) Structure
of eCPMV, chimera image created using PDB file 1NY7 (CPMV) (C,D) Purified eCPMV particles
were characterized for structural integrity using TEM and size exclusion chromatography (FPLC).
(E) One-step-NHS chemistry was used to bioconjugate Cy5 dyes to the lysine residues on eCPMV
CPs. (F) SDS-gel electrophoresis was used to confirm conjugation of Cy5 dyes to eCPMV coat proteins:
the fluorescence derived from conjugated Cy5 is detected by exposing the gel to 632 nm excitation;
the small (S) and large (L) protein are detected after protein staining (GelCode™ Blue Safe protein stain)
and visualization under white light.
Following the intracranial injection, presence and retention of VLPs in brain was detected using
ex vivo Maestro fluorescence imaging (Figure 2A). At 24 h post injection eCPMV can be readily detected
at and around the injection site as evident by a strong fluorescent signal, whereas at day 7 the weak signal
intensity suggested degradation and loss of proteinaceous VLPs from the brain microenvironment
(Figure 2A). This observation is consistent with clearance of viral nanoparticles from other tissues [31].
During this period, mice were monitored for any signs of stress and discomfort resulting from particle
administration and no apparent adverse effects were observed. We also evaluated intravenous route
for eCPMV VLP administration as a mean of delivery immunotherapy to the brain. However, the
VLPs were sequestered in the liver and spleen by the mononuclear phagocyte system (MPS) system
with minimal doses reaching other tissues, including the brain. Therefore, we selected the intracranial
injection as the mode of delivery for our studies. Based on the weeklong retention of eCPMV in brain,
we set weekly intratumoral administration schedules for glioma immunotherapy.
Cancers 2019, 11, 515 5 of 16
Cancers 2019, 11, x 5 of 17 
 
Figure 2. Intracranial eCPMV injection and immunotherapy. (A) eCPMV retention in brain 
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imaging system. (B) For in situ immunotherapy, C57BL6 mice (n = 4) were inoculated with 3 × 103 
GL261 cells intracranially and administered PBS or eCPMV via intracranial injections on days 8, 16 
and 24. (C) On day 30, MRI imaging (7 Tesla) was used to visualize glioma post-treatment. Yellow 
circles highlight solid tumors in PBS administered mice, whereas blue circle highlights the residual 
tumor and/or edema in one of the mice in the eCPMV treatment group. 
Next, we assessed the immunotherapeutic potential of the eCPMV in situ vaccine in a mouse 
model of GL261 glioma. This syngeneic model based on immunocompetent mice is one of the most 
widely used animal models for gliomas [32]. C57BL6 mice were challenged with syngeneic GL261 
tumors via intracranial injections of 3 × 103 cells in 3 μL of PBS. Pre-treatment MRI was performed 
on day 6 post-tumor inoculations to establish onset of tumor growth; then mice were randomly 
assigned to treatment groups (Figure 2B). eCPMV immunotherapy at a dose of 50 μg VLP in 3 μL 
sterilized PBS was administered via weekly intracranial injections starting on day 8 post tumor 
inoculation. The control group received sterile PBS. Mice were observed for signs associated with 
glioma progression including weight loss, irregular breathing, hunched back and decreased 
activity; upon appearance of these signs, mice were euthanized. Following three intracranial 
injections, a second MRI was performed on day 30 post-tumor inoculations to assess treatment 
efficacy (Figure 2B). 
Representative brain MRI images from PBS or eCPMV treated mice highlighted the therapeutic 
effects of the eCPMV in situ vaccination. Untreated mice developed large intracranial tumors by 
day thirty following the tumor inoculation (Figure 2C, upper panel; area marked with orange 
circle). In some mice, peritumoral edema was also observed as bright spots at the tumor edges. 
These mice also displayed the characteristic neurological and physiological symptoms associated 
with glioma including hunched posture, lack of activity and labored breathing. In stark contrast, 
Figure 2. Intracranial eCPMV injection and immunotherapy. (A) eCPMV retention in brain following
intracranial administration was determined using eCPMV-Cy5 and Maestro fluorescence imaging
system. (B) For in situ immunotherapy, C57BL6 mice (n = 4) were inoculated with 3 × 103 GL261 cells
intracranially and administered PBS or eCPMV via intracranial injections on days 8, 16 and 24. (C) On
day 30, MRI imaging (7 Tesla) was used to visualize glioma post-treatment. Yellow circles highlight
solid tumors in PBS administered mice, whereas blue circle highlights the residual tumor and/or edema
in one of the mice in the eCPMV treatment group.
Next, we assessed the immunotherapeutic potential of the eCPMV in situ vaccine in a mouse
model of GL261 glioma. This syngeneic model based on immunocompetent mice is one of the most
widely used animal models for gliomas [32]. C57BL6 mice were challenged with syngeneic GL261
tumors via intracranial injections of 3 × 103 cells in 3 µL of PBS. Pre-treatment MRI was performed on
day 6 post-tumor inoculations to establish onset of tumor growth; then mice were randomly assigned to
treatment groups (Figure 2B). eCPMV immunotherapy at a dose of 50 µg VLP in 3 µL sterilized PBS was
administered via weekly intracranial injections starting on day 8 post tumor inoculation. The control
group received sterile PBS. Mice were observed for signs associated with glioma progression including
weight loss, irregular breathing, hunched back and decreased activity; upon appearance of these signs,
mice were euthanized. Following three intracranial injections, a second MRI was performed on day 30
post-tumor inoculations to assess treatment efficacy (Figure 2B).
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Representative brain MRI images from PBS or eCPMV treated mice highlighted the therapeutic
effects of the eCPMV in situ vaccination. Untreated mice developed large intracranial tumors by
day thirty following the tumor inoculation (Figure 2C, upper panel; area marked with orange circle).
In some mice, peritumoral edema was also observed as bright spots at the tumor edges. These mice
also displayed the characteristic neurological and physiological symptoms associated with glioma
including hunched posture, lack of activity and labored breathing. In stark contrast, eCPMV-treated
mice showed absence of tumors or appeared to have regressed intracranial tumors (Figure 2C, lower
panel) suggesting a therapeutic effect of the intratumoral eCPMV administrations. Presence of cerebral
edema (blue circle) indicates stimulation of an inflammatory response to the in situ eCPMV.
To validate the underlying immunology of the eCPMV in situ vaccine, we used flow cytometry
and IHC analysis. For flow cytometry, brains were harvested from immunized mice 24 hours post
single or three weekly eCPMV administrations (Figure 3A). The single cell suspension from brains that
received a single dose of CPMV VLPs were used for characterization of the innate immune response
(Figure 3A) whereas tissues and cells derived from animals that received multiple eCPMV doses were
used to characterize the adaptive immune response (Figure 3B). Flow cytometry analysis after a single
intracranial injection indicates enhanced immune cells infiltration into the brain of mice receiving
eCPMV in situ vaccine (black bars) over tumor bearing mice receiving PBS (white bars). Specifically,
eCPMV treated mice showed significantly elevated levels of leukocytes (CD45+ cells), CD11b+CD11c+
DCs, CD11bint-lowNK1.1+ NK cells, CD11b+Ly6G−monocytes, and CD11b+Ly6G+MHCII+CD86+ TINs
compared with PBS-treated tumor bearing mice. Several other immune cells including macrophages,
granulocytes, activated neutrophils and G-MDSCs showed an increasing trend, but were not statistically
significantly different from PBS treated mice.
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adaptive (C) immune cell infiltrates in eCPMV treated (black bars) or untreated (white bars) GL261 
bearing brain tissues. Error bars represent SEM. Statistical comparisons were performed using 
unpaired t-test (**** p < 0.0001, *** p < 0.001, ** p < 0.01 and * p < 0.05). 
The innate response to the in situ vaccine is consistent with our earlier studies using mouse 
models of melanoma [33]. Here, we observed monocytes being recruited; in particular elevated 
levels of CD11b+Ly6G− monocytes in eCPMV-treated brain could suggest local inflammation in 
response to the intracranial injection of the VLPs. Further, both monocytic CD11b+CD11c+ DCs and 
CD11b+F4/80+ macrophages were elevated in response to eCPMV immunotherapy. Additionally, 
eCPMV treatment also resulted in significant influx of the CD11b+Ly6G+MHCII+CD86+ tumor 
Figure 3. Flow cytometry nalysis to charact rize immune infiltration in the b ain parenchyma.
(A) GL261 glioma bearing C57BL6 mice (n = 3) wer tr ated 1× or 3×with eCPMV immunother py and
the brain tissues were harvested 24 h following the last treatments to determine innate (B) and adaptive
(C) immune cell infiltrates in eCPMV treated (black bars) or untreated (white bars) GL261 bearing
brain tissues. Error bars represent SEM. Statistical comparisons were performed using unpaired t-test
(**** p < 0.0001, *** p < 0.001, ** p < 0.01 and * p < 0.05).
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The innate response to the in situ vaccine is consistent with our earlier studies using mouse
models of melanoma [33]. Here, we observed monocytes being recruited; in particular elevated levels
of CD11b+Ly6G− monocytes in eCPMV-treated brain could suggest local inflammation in response to
the intracranial injection of the VLPs. Further, both monocytic CD11b+CD11c+ DCs and CD11b+F4/80+
macrophages were elevated in response to eCPMV immunotherapy. Additionally, eCPMV treatment
also resulted in significant influx of the CD11b+Ly6G+MHCII+CD86+ tumor infiltrating neutrophils
(TINs) that also displayed high expression levels of CD86 and MHCII molecules (Figure 3B).
Next, brain tissues harvested from mice following three treatments of eCPMV or PBS were
analyzed by flow cytometry to evaluate the role of adaptive immunity (Figure 3C). Unlike the innate
response, tumor-specific CD8+ and CD4+ T cells proliferate in an antigen-specific manner following
stimulation by APCs. The potent innate response generated by the eCPMV in situ vaccine indeed led
to significant recruitment of CD3+ T cells. Specifically, CD8+ T cell levels were significantly higher in
eCPMV-treated mice over PBS-treated tumor-bearing mice. The increase in the CD4+ T cell population
was not significantly different comparing eCPMV-vs PBS-treated tumor-bearing mice. A similar
trend was observed for the effector memory T cells (EMTs), where a significant increase in the levels
of CD8+ CD44+ CD62L− EMTs and a non-significant increase in the levels of CD4+CD44+CD62L−
EMTs was noted comparing eCPMV- vs. PBS-treated animals. Interestingly, eCPMV treated mice
also demonstrated significantly enhanced levels of CD3+NK1.1+ NKT cells. Overall, these results
demonstrate efficient recruitment of both innate and adaptive immune cells to the brain tissue as a result
of the eCPMV in situ vaccination, indicating that the anti-tumor response is indeed immune-mediated.
Finally, we used immunohistochemistry (IHC) to characterize the changing cellular landscape of
the innate immune system within the glioma itself. To gauge the effects of single or multiple doses of
eCPMV, brains from tumor-bearing mice were harvested 24 h after either a single dose or three doses
(Figure 4A). Fixed tissue sections were then stained for immune cell markers IBA-1, CD68, CD45 and
FoxP3 and cellular densities were quantified using Zeiss image analysis program (Axiovision Rel 4.5,
Zeiss, Thornwood, NY, USA) (Figure 4B). IHC staining revealed significantly elevated levels of CD45+
leucocytes in the tumor tissue following the eCPMV treatment, which mirrors the flow cytometry data
indicating an overall increase in the CD45+ cells in the brain parenchyma. When compared to a single
administration, the overall CD45+ optical density doubled following three doses of eCPMV in situ
vaccine; this may indicate engagement of adaptive cell response that results in an influx of effector
cells including T lymphocytes and NKT cells. Further, we quantified the changes in IBA-1 and CD68
expression to evaluate microglia/macrophage (IBA-1/CD68) invasion into the tumors. As observed in
IHC panel (Figure 4B), eCPMV administration resulted in increased intratumoral expression levels
of both IBA-1 and CD68. We also compared the population of Tregs in glioma bearing mice with
and without CPMV immunotherapy by staining for FoxP3 expression, which is a regulatory T cells
specific transcription factor [34]. Our results indicate abundance of FoxP3+ Tregs in non-treated glioma,
whereas a significant reduction in intratumoral FoxP3+ Tregs is observed with CPMV immunotherapy
(Figure 4B).
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Figure 4. Immunohistochemical analysis. ( ) issues from GL261 glioma bearing mice (n = 3)
were ha vested on day 25 from tumor inoculation af of receiving 1× eCPMV reatment or the
last dose of 3× eCPMV treatment. (B) Tumor sections (6 µm thick) were stained with α-CD45 antibody,
α-IBA-1 antibody, α-CD68 antibody and α-FoxP3 antibody. The scale bar is 50 µm in all images.
Quantitative analysis was performed using Zeiss software to determine relative optical densities of the
stained sections. Error bars represent SEM. Statistical analysis was performed using ordinary one-way
ANOVA (Tukey’s multiple comparison test (**** p < 0.0001, *** p < 0.001, ** p < 0.01).
3. Discussion
We and others have demonstrated that intratumorally administered VLPs can modulate the local
tumor microenvironment via recruitment and activation of immune cells [25,35]. The immunomodulatory
properties of VLPs arise from the repetitive architectures of the coat proteins that present potent
pathogen-as ociated molecular patterns (PAMPs) [36]. VLPs are recognized by TLRs [37] and TLR
signaling can stimulate innate as well a adap ive immune responses. Previously, GL261 cell have
also been shown to express TLR2, TLR3 and TLR4, and TLR ligands have been used as treatments
against established glioma [38,39]. Here we show that intratumoral administration of the eCPMV VLP
generates an antitumor immune response leading to immunological regression of glioma. In some
cases, inflammatory responses were also noted. The formation of such cerebral edema induced
by inflammatory response has been previously observed following glioma radiotherapy [40] and
oncolytic viral therapies [41]. The risk management of the immune responses in the brain as part of the
immunotherapy will require future detailed investigation.
Profiling of the innate and adaptive immune cells following the in situ vaccination provides insight
into the mechanism. Consistent with our previous studies in other tumor models, the innate immune cell
cohort consists of monocytic DCs and macrophages and TINs. TINs have been identified as the primary
modulators of the anti-tumor innate responses. Direct physical contact between neutrophils and cancer
cells has been shown as a pre-requisite for cancer cell cytotoxicity. The cytotoxicity is attributed to
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neutrophil-secreted H2O2 that induces influx of Ca2+ in cancer cells leading to apoptosis [42] or to
neutrophil Fas ligand-cancer cell Fas receptor interactions, which stalls tumor cell cycle progression
from G1 to S phase [43]. In addition to direct cytotoxicity, neutrophils also mediate anti-tumor immune
response through recruitment of effector immune cells. Pro-inflammatory N1 neutrophils promote
CD8+ T recruitment and activation by secreting chemokines (e.g., CCL3, CXCL9, and CXCL10) and
cytokines (e.g., IL-12, TNF-α, GM-CSF) that attract T cells [44]. Moreover, neutrophils can also
coordinate adaptive immune responses through interactions with dendritic cells [44].
Another significant population of infiltrating innate immune cells was identified as NK cells.
NK cells are among the most potent cytotoxic cells against tumor cells and high levels of tumor
infiltrating NK cells are associated with a favorable tumor outcome in patients [45]. Transformed
cells with reduced or absent MHC-I expression are therefore NK cells targets. Additionally, cellular
stress and DNA damage results in upregulation of NK cell activation ligands on tumors. NK cells
can kill tumor cells by releasing cytolytic granules containing perforin and granzymes, which leads to
cancer cell apoptosis; NK cells also induce death receptor-mediated apoptosis [45,46]. Furthermore,
activated NK cells secrete IFN-γ that can induce CD8+ T cells to CTL transformation and promote
CD4+ T cells towards Th1 response, which promotes CTL differentiation. NK cells also promote
recruitment of conventional DC-type 1 (cDCs) in the tumor microenvironment via secreted CCL5 and
XCL1 cytokines [47]. cDCs are particularly efficient in carrying tumor antigens and cross presenting
them to CD8 T cells to stimulate an adaptive immune response [48]. Therefore, tumor antigens released
from cells lysed by activated NK cells can be taken up by APCs including the DCs and TINs described
above, which subsequently can contribute towards development of an adaptive immune response
mediated by tumor-specific CTLs [45].
Recent advances in the understanding of the structural and functional aspects of CNS lymphatic
vessels have revealed the mechanism of CNS immune surveillance, including the entrance and exit
of immune cells [11]. Functional studies of such meningeal lymphatic vessels have revealed their
role in transporting CD11c+ cells, B220+ cells and T cells. Additionally, these meningeal lymphatic
vessels have been shown connected to deep cervical lymph nodes, which are known to elicit immune
responses to antigens from cerebrospinal fluids [49,50]. Thus, APCs carrying tumor antigens from
lysed cells following eCPMV treatment are likely transported to the draining deep cervical lymph
nodes and present the tumor antigens to naïve T cells resulting in expansion of tumor antigen specific
adaptive immune response.
Indeed, our data indicate engagement of cells of the adaptive immune system. We note a significant
increase in CD8+ T cells levels, effector memory CD8 T cells and NKT cells. NKTs are a unique lineage
of innate T cells that express markers for T lymphocytes as well as NK cells. These cells can kill tumor
cells by direct cytolysis using perforin and granzyme B, but also by modulating the recruitment of other
effector immune including T cells, B cells, NK cells and DCs [51]. Thus, NKT cells may also play a key
role in linking the innate and adaptive immune response against tumors. NKT cells can also reverse
the immunosuppression mediated by MDSCs and tumor associated macrophages [52]. In the case of
glioma that display highly immunosuppressive tumor microenvironment, the role of NKT as boosters
of adaptive immune response and suppressor of immune regulation is therefore considered critical.
Furthermore, IHC highlighted the changing immunological landscape following in situ vaccination
with eCPMV. Our data indicate significantly elevated levels of CD45+ cells in the brain paranchyma
following CPMV administration, which corroborates earlier studies in melanoma models where
intratumoral administrations of CPMV lead to massive influx of effector immune cells [33]. In particular,
we observed enhanced influx of IBA-1/CD68+ microglia/macrophage cells. Microglia are the resident
innate immune cells of CNS that participate in immune surveillance and host defense against infectious
agents. Together with infiltrating bone marrow-derived macrophages, microglia functions to restore
homeostasis in brain parenchyma to counter inflammatory responses including malignancies. The dual
role of microglia/macrophages in gliomas has been extensively studied. Under immunosuppressive
TME, microglia/macrophages appear to promote glioma proliferation and invasiveness [53,54].
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However, microglia-secreted factors and TLR agonists have been shown to simulate apoptosis
in glioma cells [55,56]. Also, while genetic ablation of monocytoid cells has been shown to promote
glioma, drug mediated activation of monocytoid cells in brain results in microglia-mediated reduction
of brain tumor initiating cells [57]. This functional duality has been attributed to the polarization of
microglia to tumor suppressive M1 and tumor supportive M2 cells [58,59]. M1 cells are activated
by type I cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) and other
immunostimulants such as lipopolysaccharide (LPS), and lipoproteins. The activated M1 polarized
microglia have been shown to possess antigen-presenting capabilities to Th1 cells leading to anti-tumor
CTL activity [58]. CPMV has been shown to stimulate IFN-γ and TNF-α in the TME in our previous
studies, and therefore is likely to influence the glioma TME similarly. These results are consistent with
elevated staining observed in glioma treated with LPS or myeloid cell activation agents that also lead
to increased iNOS expression (M1 phenotype) and a significant reduction in tumor volumes [57].
Tumor-mediated immune suppression is a critical barrier to glioma immunotherapies. In addition
to M2 polarized microglia/macrophages described above, regulatory T cells (Tregs) accumulated
in the TME contribute to glioblastoma-mediated immune suppression [60]. In high grade brain
tumors, Tregs suppress activation, proliferation and cytokine production of CD4+/CD8+ T cells via
secreted cytokines such as TGF-B and IL-10 or via cell-to cell contact mediated by the constitutively
expressed CTLA-4 and PD-L1 checkpoints [61]. Thus, expansion of Tregs is associated with decreased
efficacy of immunotherapies and therapeutic targeting of Tregs has been used to improve survival
in glioma studies [62,63]. The significant reduction in intratumoral FoxP3+ Tregs following CPMV
immunotherapy mirrors the effects of intratumoral IL-12+ CTLA-4 combination therapy which enhanced
infiltration of CD4/CD8 cells while significantly reducing the FoxP3+ Tregs [64]. Pro-inflammatory
cytokines including IL-12 are key component of eCPMV-mediated immune response and likely
contribute to reduced Tregs population in the glioma TME [25,33]. Overall, eCPMV immunotherapy
leads to an effective reversal of the immunosuppressive tumor microenvironment. In conjugation
with the elevated CD8+ T cells and NKT cells infiltration and enhanced activation of resident
microglia, this immunomodulation renders the glioma TME conducive for progression of an anti-tumor
immune response.
4. Materials and Methods
4.1. Production of eCPMV VLPs
eCPMV VLP was produced as described elsewhere [25,27]. Briefly, Agrobacterium LBA4404
cultures harboring the binary plasmid pEAQexpress-VP60-24K that encodes the coat protein precursor
VP60 and viral proteinase 24K, were introduced into N. benthamiana leaves using syringe-infiltration.
Infiltrated tissue was harvested 6 days post-infiltration, homogenized in 0.1 M sodium phosphate buffer
(pH 7.0) and purified using established protocols [27]. VLP concentration was determined by UV/vis
spectroscopy (ε280 nm = 1.28 mg−1 mL cm−1). Particle integrity was examined using transmission
electron microscopy (TEM) on a FEI Technai20 and by size exclusion chromatography using a Superose
6 column on the AKTA Explorer chromatography system (GE Healthcare, Chicago, IL, USA).
4.2. Synthesis and Characterization of eCPMV-Cy5 Particles
eCPMV VLPs were covalently modified with Cy5 using N-hydroxysuccinimide-activated ester
targeting surface exposed lysine residues on the capsid. Briefly, 3000 molar excess of Sulfo-Cyanine5
NHS ester (NHS-Sulfo Cy5) were reacted with eCPMV in 0.1M KP buffer at final protein concentration
of 2 mg/mL in presence of 10% (v/v) DMSO. Following overnight reactions, eCPMV-Cy5 was purified
from unconjugated reactants over a 40% (w/v) sucrose cushion at 160,000× g for 3 h and resuspended
in sterile KP buffer. UV spectroscopy was used to determine the eCPMV-Cy5 concentrations and to
determine Cy5/VLPs ratios using molar extinction coefficient εeCPMV of 1.28 mL mg−1 cm−1 at 280 nm
and sulfo-Cy5-specific molar extinction coefficient εCy5 of 271,000 at 660 nm.
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The conjugation of fluorophore on eCPMV was determined using SDS-gel electrophoresis. Briefly,
10 µg of unmodified eCPMV and eCPMV-Cy5 mixed with SDS running buffer and heated at 100 ◦C
for 5 min were loaded on pre-cast NuPAGE™ 4–12% Bis-Tris proteins gels (ThermoFisher Scientific,
Hampton, NH, USA) and electrophoresis was performed for 40 min at 200 V. Fluorescent bands
representing Cy5 modified eCPMV coat proteins were visualized on an AlphaImage gel documentation
system (Protein simple) using a 632 nm excitation. The gels were then stained using GelCode™ Blue
Safe protein stain (ThermoFisher Scientific).
4.3. Cell Line
GL261 cell line was obtained from the Tumor Repository at National Cancer Institute (NCI) and
maintained in suspension culture prior to engraftment intracranially. Briefly, cells were grown in
a suspension flask (CytoOne, CC-672-4175, USA Scientific, Oscala, FL, USA) and kept in a 5% CO2
37 ◦C humidified incubator in serum-free neuro medium (MACs neuro medium with Neurobrew-21
(130-093-570 and 130-097-263 respectively, Miltenyi Biotec Inc., Auburn, CA, USA), 20 ng/mL EGF
(AF-100-15, Peprotech, Rocky Hill, NJ, USA) and 20 ng/mL FGF (100-18B, Peprotech) with 1% (w/v)
pencillin-streptomycin (15140122, Gibco Invitrogen, Waltham, MA, USA) and 1% (w/v) L-glutamine
(25030081, Gibco Invitrogen). Cultured cells were pelleted and re-suspended in media to 3 × 103 cells
per 3 µL in growth medium and placed on ice prior to implantation.
4.4. Tumor Inoculation
All mouse studies were performed in compliance with the Institutional Animal Care and Use
Committee of Case Western Reserve University (Assurance number is A-3145-01, valid until 20 April 2019).
Immunocompetent animals (C57BL6, Jackson Labs, Bar Harbor, MA, USA), 4–6 weeks of age, males
and females, were utilized for intracranial implantation of GL261 cells (n = 4). Briefly, animals were
placed under anesthesia (inhaled isoflurane). Once fully anesthetized, lidocaine was applied and a
small incision was made through the scalp and the bregma was identified. A small 25-gauge burr
hole was made 2 mm caudal and 3 mm to the right of bregma. A 22-gauge Hamilton syringe (88011,
ThermoFisher Scientific) was inserted and placed 3 mm below the skull and then retracted 0.5 mm to
establish a pocket for implantation of cells. Cells, 3 × 103 cells per 3 µL PBS, were slowly injected into
the right frontal lobe and the Hamilton syringe was held in place for 3 min post injection to prevent
reflux. The burr hole was sealed with bone wax and the incision was closed with surgical glue and
non-dissolvable sutures. Animals were given analgesia and maintained on a heating pad until recovery.
Control and CPMV treated animals were placed under anesthesia weekly and given intratumoral
injections of either vehicle or CPMV (50 µg) in 3 µL dosages. Injections were made within the same
burr hole as done with inoculation of tumor. This was performed weekly for a total of 3 weeks.
Care and housing of the animals was provided by the University Animal Resource Center following
IACUC oversight. The facility follows recommendations from the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. Mice were maintained in microisolator cages and exposed to
12 h light/12 h darkness cycles with standard food and water ad libitum. Mice were weighed weekly and
checked daily for tumor growth symptoms according to the IACUC tumor burden policy.
4.5. Small Animal MRI
MRI imaging was performed prior to start of immunotherapy at day 6 from tumor inoculation
and post-treatment on day 30. The in vivo MRI studies were performed on the same Biospec 7 T
scanner equipped with a 3 cm birdcage 1H coil (Bruker, Erlangen, Germany). During MR imaging, mice
were anesthetized by isoflurane, respiration rate was maintained at 70–80/min. After reaching surgical
plane of anesthesia, the mouse was placed on an animal holder with its nose inserted into a nose cone.
A head restrainer was utilized to prevent potential motion. An animal monitoring system was in place
to monitor body temperature and respiration/cardiac cycle. After securing the animal and monitoring
the components, the animal was positioned at the center of the RF coil. The RF coil was placed into the
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magnet. We conducted shimming process using a single pulse sequence and the RF pulse was maximized
to keep the pulse length constant and a long enough recycle delay to conduct an image. A fast image
acquisition was used to acquire sample images to determine animal placement and imaging setup.
4.6. Flow Cytometry
The following antibodies and reagents were used for flow cytometry, all obtained from BioLegend
(San Diego, CA, USA): Pacific Blue anti-mouse CD45 (clone 30-F11), FITC anti-mouse CD11b (clone
M1/70), APC anti-mouse CD11c (clone N418), PE anti-mouse F4/80 (clone BM8), Brilliant Violet 605
anti-mouse CD86 (clone GL-1), Alexa Fluro 700 anti-mouse I-A/I-E (clone M5/114.15.2), APC/Cy7
anti-mouse CD3 (clone 145-2C11), FITC anti-mouse CD4 (clone Gk1.5), APC anti-mouse CD8 (clone
53-6.7), Alexa Fluor 700 anti-mouse CD25 (clone PC61), PE anti-mouse FOXP3 (clone MF-14), Zombie
yellow fixable viability kit, and anti-mouse CD16/32 (clone 93). GL261 Glioma bearing mice (n = 3)
were treated once or thrice with CPMV immunotherapy or PBS and brain tissues were harvested 24 h
following the intratumoral therapy. Single-cell suspensions were prepared as previously described [25]
and incubated for 15 min at 4 ◦C with a CD16/CD32 antibody (diluted in PBS) to block Fc receptors
before washing with PBS. Tumor cells harvested on following single CPMV dose were tested using
the innate panel and were incubated at 4 ◦C in triplicate with the cocktail of zombie yellow viability,
CD45, CD11b, CD11c, F4/80, CD86 and I-A/I-E antibodies diluted in PBS. Tumor cells harvested
at 24 h following three doses of CPMV immunotherapy were tested using the adaptive panel and
were incubated at 4 ◦C in triplicate with the cocktail of zombie yellow viability, CD45, CD3, CD25,
CD4, CD8 and FOXP3 antibodies. Cells were washed twice with PBS and then fixed with 3% (v/v)
paraformaldehyde for flow cytometry using an LSR II (BD Biosciences, San Jose, CA, USA). The data
were analyzed using the FlowJo v8.6.3 software (Flow Jo, Ashland, OR, USA).
4.7. Immunohistochemistry and H&E-Staining
Brain tissues harvested from treated and untreated mice (n = 3) were fixed in 10% (v/v)
buffered formalin, embedded in paraffin, sectioned at 6 µm, and mounted on Superfrost® Plus
slides (12-550-15, ThermoFisher Scientific). Sections were then hydrated through descending ethanol
to water. Endogenous peroxidase activity was eliminated by incubation in 3% (v/v) H2O2 for 30 min
prior to heat induced epitope retrieval (HIER). HIER was performed using a citrate based retrieval
buffer, pH 6.1 (S1699, Dako, Santa Clara, CA, USA) for 10 min in a 96 ◦C water bath. The mouse antigen
blocking kit (PK-2200, Vector laboratories, Burlingame, CA, USA) was utilized to reduce background
staining according to manufacturer protocols for mouse derived antibodies. To reduce non-specific
binding sections were incubated in 10% (v/v) normal goat serum (PCN5000, ThermoFisher Scientific) in
Tris-buffered saline, (TBS; 50 mM Tris-HCl 150 mM NaCl, pH 7.6, Bio-Rad, 170-6435, Hercules, CA,
USA) for 30 min prior to application of the primary antibody. Antibodies used in this study were
mouse monoclonal antibody specific CD68 (ab201340, Abcam, Cambridge, UK) and rabbit monoclonal
antibodies to IBA1 (ab178846, Abcam); CD45 (ab10558, Abcam) and Foxp3 (700914, Invitrogen, Camarillo,
CA, USA). Immunohistochemistry was visualized via the peroxidase-anti-peroxidase method using
3,3′-diaminobenzidine (DAB) as a chromogen (TA-125-QHDX, ThermoFisher Scientific, Waltham, MA,
USA). Serial sections were stained with hematoxylin and eosin to note the areas of tumor cell growth.
Images were acquired with an Azio Scope A.1 (Zeiss, Thronwood, NY, USA) from three adjacent fields
containing tumor. The immunoreactive intensity of positive cells were measured utilizing the Zeiss
image analysis program (Axiovision Red 4.5, Zeiss) with background levels substracted from the stroma
of the tumor. Statistical analysis was completed by ordinary one-way ANOVA using the Tukey’s
multiple comparisons test on the GraphPad Prism software (GraphPad Software, San Diego, CA, USA).
5. Conclusions
In conclusion, our results illustrate that eCPMV-mediated modulation of the immunological
landscape in the brain TME supports anti-tumor response in our murine model. With its non-pathogenic
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and non-replicating nature, ability to reverse the tumor immunosuppression and recruit immune
effector cells, eCPMV nanoparticles offer a promising immunotherapy for glioma. In this study,
we performed multiple intracranial treatments; in the future one may consider the development of
slow-release formulations, or continuous low flow infusion to better control the immune response and
alleviate the edema and complications associated with immunotherapy. Delivery of therapeutics to the
brain is an active area of research that has evolved from biodegradable polymer implants [65,66] to
more recent miniaturized implantable system MiNDS [67]. We have already developed and tested
slow-release formulations for VLP vaccines [68], including in situ vaccines [69]. By formulating
slow-release devices or implants incorporating VLPs, it will likely be possible to circumvent the need
for repeated invasive administrations; thereby improving the translational potential of plant virus
based immunotherapy for glioma.
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